Advanced BioNutrition (ABN) was awarded a $1.7 million contract from the DoD for the first phase of development of a shrimp-based production system for vaccines and mAbs.
The contracts from the Defense Advanced Research Projects Agency (DARPA) and the Defense Threat Reduction Agency (DTRA) could reach $5.9 million over 42 months if all phases of the agreement are completed successfully, according to the company.
Arun K. Dhar, Ph.D., a molecular virologist at ABN will be leading the three-phase program with a goal of producing three million doses of vaccine or immunological-based therapeutic within 12 weeks of the first recognition of a new pathogen, ABN reports.
During the first phase of the contract, ABN plans to validate the use of crustaceans as biofactories using its transfection technology. The company reports that it is also developing a high-density GMP-capable production system for shrimp cultivation as well as methods for the isolation and purification of the final products.